期刊文献+

NOD2 mutations and colorectal cancer - Where do we stand?

NOD2 mutations and colorectal cancer-Where do we stand?
下载PDF
导出
摘要 Due to the overwhelming burden of colorectal cancer(CRC), great effort has been placed on identifying genetic mutations that contribute to disease development and progression. One of the most studied polymorphisms that could potentially increase susceptibility to CRC involves the nucleotide-binding and oligomerization-domain containing 2(NOD2) gene. There is growing evidence that the biological activity of NOD2 is far greater than previously thought and a link with intestinal microbiota and mucosal immunity is increasingly sought after. In fact, microbial composition may be an important contributor not only to inflammatory bowel diseases(IBD) but also to CRC. Recent studies have showed that deficient NOD2 function confers a communicable risk of colitis and CRC. Despite the evidence from experimental models, population-based studies that tried to link certain NOD2 polymorphisms and an increase in CRC risk have been described as conflicting. Significant geographic discrepancies in the frequency of such polymorphisms and different interpretations of the results may have limited the conclusions of those studies. Since being first associated to IBD and CRC, our understanding of the role of this gene has come a long way, and it is tempting to postulate that it may contribute to identify individuals with susceptible genetic background that may benefit from early CRC screening programs or in predicting response to current therapeutic tools. The aim of this review is to clarify the status quo of NOD2 mutations as genetic risk factors to chronic inflammation and ultimately to CRC. The use of NOD2 as a predictor of certain phenotypic characteristics of the disease will be analyzed as well. Due to the overwhelming burden of colorectal cancer(CRC), great effort has been placed on identifying genetic mutations that contribute to disease development and progression. One of the most studied polymorphisms that could potentially increase susceptibility to CRC involves the nucleotide-binding and oligomerization-domain containing 2(NOD2) gene. There is growing evidence that the biological activity of NOD2 is far greater than previously thought and a link with intestinal microbiota and mucosal immunity is increasingly sought after. In fact, microbial composition may be an important contributor not only to inflammatory bowel diseases(IBD) but also to CRC. Recent studies have showed that deficient NOD2 function confers a communicable risk of colitis and CRC. Despite the evidence from experimental models, population-based studies that tried to link certain NOD2 polymorphisms and an increase in CRC risk have been described as conflicting. Significant geographic discrepancies in the frequency of such polymorphisms and different interpretations of the results may have limited the conclusions of those studies. Since being first associated to IBD and CRC, our understanding of the role of this gene has come a long way, and it is tempting to postulate that it may contribute to identify individuals with susceptible genetic background that may benefit from early CRC screening programs or in predicting response to current therapeutic tools. The aim of this review is to clarify the status quo of NOD2 mutations as genetic risk factors to chronic inflammation and ultimately to CRC. The use of NOD2 as a predictor of certain phenotypic characteristics of the disease will be analyzed as well.
出处 《World Journal of Gastrointestinal Surgery》 SCIE CAS 2016年第4期284-293,共10页 世界胃肠外科杂志(英文版)(电子版)
关键词 Colorectal CANCER FECAL microbiota CANCER susceptibility Intestinal inflammation NUCLEOTIDE-BINDING and oligomerization-domain containing 2 MUTATIONS Colorectal cancer Fecal microbiota Cancer susceptibility Intestinal inflammation Nucleotide-binding and oligomerization-domain containing 2 mutations
  • 相关文献

参考文献1

二级参考文献13

  • 1Martin Lacher,Johanna Helmbrecht,Sebastian Schroepf,Sibylle Koletzko,Antje Ballauff,Martin Classen,Holm Uhlig,Jochen Hubertus,Dominik Hartl,Peter Lohse,Dietrich von Schweinitz,Roland Kappler.NOD2 mutations predict the risk for surgery in pediatric-onset Crohn’s disease[J].Journal of Pediatric Surgery.2010(8)
  • 2Bas Oldenburg,Daan Hommes.Biological therapies in inflammatory bowel disease: top-down or bottom-up?[J].Current Opinion in Gastroenterology.2007(4)
  • 3António CarlosFerreira,SusanaAlmeida,MartaTavares,PauloCanedo,FábioPereira,Gon?aloRegalo,CéuFigueiredo,EuniceTrindade,RaquelSeruca,FátimaCarneiro,JorgeAmil,José CarlosMachado,FernandoTavarela‐Veloso.NOD2/CARD15 and TNFA, but not IL1B and IL1RN, are associated with Crohn’s disease[J].Inflamm Bowel Dis.2006(4)
  • 4Julia Seiderer,Fabian Schnitzler,Stephan Brand,Tanja Staudinger,Simone Pfennig,Karin Herrmann,Katrin Hofbauer,Julia Dambacher,Cornelia Tillack,Michael Sackmann,Burkhard G?ke,Peter Lohse,Thomas Ochsenkühn.Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn’s disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis[J].Scandinavian Journal of Gastroenterology.2006(12)
  • 5Manuel Alvarez-Lobos,Juan I. Arostegui,Miquel Sans,Dolors Tassies,Susana Plaza,Salvadora Delgado,Antonio M. Lacy,Josep M. Pique,Jordi Yagüe,Julián Panés.Crohn?s Disease Patients Carrying Nod2/CARD15 Gene Variants Have an Increased and Early Need for First Surgery due to Stricturing Disease and Higher Rate of Surgical Recurrence[J].Annals of Surgery.2005(5)
  • 6L.LAGHI,S.COSTA,S.SAIBENI,P.BIANCHI,P.OMODEI,A.CARRARA,L.SPINA,E.CONTESSINI AVESANI,M.VECCHI,R.DE FRANCHIS,A.MALESCI.Carriage of CARD15 variants and smoking as risk factors for resective surgery in patients with Crohn’s ileal disease[J].Alimentary Pharmacology & Therapeutics.2005(6)
  • 7Subra Kugathasan,Nicole Collins,Karen Maresso,Raymond G. Hoffmann,Michael Stephens,Steven L. Werlin,Colin Rudolph,Ulrich Broeckel.CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn’s disease[J].Clinical Gastroenterology and Hepatology.2004(11)
  • 8C.Büning,J.Genschel,S.Bühner,S.Krüger,K.Kling,A.Dignass,P.Baier,B.Bochow,J.Ockenga,H. H.‐J.Schmidt,H.Lochs.Mutations in the NOD2/CARD15 gene in Crohn’s disease are associated with ileocecal resection and are a risk factor for reoperation[J].Alimentary Pharmacology & Therapeutics.2004(10)
  • 9Denis Heresbach,Véronique Gicquel-Douabin,Brigitte Birebent,Pierre-Nicolas D’halluin,Nathalie Heresbach-Le Berre,Stéphane Dreano,Laurent Siproudhis,Alain Dabadie,Michel Gosselin,Jean Mosser,Gilbert Semana,Jean-Fran?ois Bretagne,Jacqueline Yaouanq.NOD2/CARD15 gene polymorphisms in Crohn’s disease: a genotype–phenotype analysis[J].European Journal of Gastroenterology & Hepatology.2004(1)
  • 10R. W. L.Leong,A.Armuzzi,T.Ahmad,M. L.Wong,P.Tse,D. P.Jewell,J. J. Y.Sung.NOD2/CARD15 gene polymorphisms and Crohn’s disease in the Chinese population[J].Alimentary Pharmacology & Therapeutics.2003(12)

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部